NASDAQ:BOLT Bolt Biotherapeutics (BOLT) Stock Price, News & Analysis $4.84 0.00 (0.00%) Closing price 09/4/2025 04:00 PM EasternExtended Trading$4.83 -0.01 (-0.21%) As of 09/4/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock About Bolt Biotherapeutics Stock (NASDAQ:BOLT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Bolt Biotherapeutics alerts:Sign Up Key Stats Today's Range$4.84▼$4.9550-Day Range$4.84▼$6.7152-Week Range$4.59▼$14.36Volume2,938 shsAverage Volume14,239 shsMarket Capitalization$9.29 millionP/E RatioN/ADividend YieldN/APrice Target$47.50Consensus RatingHold Company Overview Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California. Read More Bolt Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreBOLT MarketRank™: Bolt Biotherapeutics scored higher than 60% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingBolt Biotherapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageBolt Biotherapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Bolt Biotherapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Bolt Biotherapeutics are expected to grow in the coming year, from ($1.61) to ($1.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bolt Biotherapeutics is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bolt Biotherapeutics is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBolt Biotherapeutics has a P/B Ratio of 0.16. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Bolt Biotherapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.79% of the float of Bolt Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverBolt Biotherapeutics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bolt Biotherapeutics has recently decreased by 7.25%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBolt Biotherapeutics does not currently pay a dividend.Dividend GrowthBolt Biotherapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.79% of the float of Bolt Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverBolt Biotherapeutics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bolt Biotherapeutics has recently decreased by 7.25%, indicating that investor sentiment is improving significantly. News and Social MediaN/ANews SentimentN/A Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Bolt Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.10% of the stock of Bolt Biotherapeutics is held by insiders.Percentage Held by Institutions86.70% of the stock of Bolt Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Bolt Biotherapeutics' insider trading history. Receive BOLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bolt Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BOLT Stock News HeadlinesBolt Biotherapeutics reports Q2 EPS ($4.46), consensus ($6.27)August 14, 2025 | msn.comBolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 14, 2025 | globenewswire.comRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns just aren’t enough anymore. But what if you could reach your Freedom Number—the monthly income that makes retirement secure—using far less money than you thought possible? That’s exactly what Kelly G. discovered. She calls it “life-changing,” saying the income just keeps growing and that early retirement suddenly looks real. This strategy was once reserved for the ultra-wealthy, but it’s now available to everyday investors. | Investors Alley (Ad)Triple Bolt Technology LLC Unveils Technical Plan for Blue Gold Token, a Gold-Backed Crypto AssetJuly 17, 2025 | quiverquant.comQBlue Gold Limited Enters Strategic Partnership with TripleBolt Technology to Launch Blockchain-based Gold-Backed Digital AssetJuly 3, 2025 | quiverquant.comQBolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 12, 2025 | globenewswire.comBolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate UpdatesMay 8, 2025 | globenewswire.comBolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025April 30, 2025 | globenewswire.comSee More Headlines BOLT Stock Analysis - Frequently Asked Questions How have BOLT shares performed this year? Bolt Biotherapeutics' stock was trading at $10.7020 at the beginning of 2025. Since then, BOLT stock has decreased by 54.8% and is now trading at $4.84. How were Bolt Biotherapeutics' earnings last quarter? Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) released its quarterly earnings results on Thursday, August, 14th. The company reported ($4.46) EPS for the quarter, beating the consensus estimate of ($6.40) by $1.94. The firm had revenue of $1.80 million for the quarter, compared to analyst estimates of $0.82 million. When did Bolt Biotherapeutics' stock split? Shares of Bolt Biotherapeutics reverse split before market open on Monday, June 9th 2025.A 1-20 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, June 8th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Bolt Biotherapeutics IPO? Bolt Biotherapeutics (BOLT) raised $150 million in an initial public offering on Friday, February 5th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Stifel and Guggenheim Securities acted as the underwriters for the IPO. Who are Bolt Biotherapeutics' major shareholders? Top institutional shareholders of Bolt Biotherapeutics include Vivo Capital LLC (9.17%), Sofinnova Investments Inc. (7.17%), Nan Fung Group Holdings Ltd (3.04%) and Board of Trustees of The Leland Stanford Junior University (1.87%). Insiders that own company stock include Edgar Engleman, Vivo Capital Viii, Llc, William P Quinn and Sarah Nemec. View institutional ownership trends. How do I buy shares of Bolt Biotherapeutics? Shares of BOLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bolt Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bolt Biotherapeutics investors own include Athenex (ATNX), NIO (NIO), Plug Power (PLUG), Alibaba Group (BABA), Moderna (MRNA), NVIDIA (NVDA) and XPeng (XPEV). Company Calendar Last Earnings8/14/2025Today9/04/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:BOLT CIK354655 Webwww.boltbio.com Phone650-665-9295FaxN/AEmployees90Year Founded2015Price Target and Rating Average Price Target for Bolt Biotherapeutics$47.50 High Price Target$75.00 Low Price Target$20.00 Potential Upside/Downside+881.4%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($26.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$63.12 million Net MarginsN/A Pretax Margin-1,217.02% Return on Equity-91.67% Return on Assets-53.19% Debt Debt-to-Equity Ratio0.56 Current Ratio3.11 Quick Ratio3.11 Sales & Book Value Annual Sales$7.69 million Price / Sales1.21 Cash FlowN/A Price / Cash FlowN/A Book Value$20.24 per share Price / Book0.24Miscellaneous Outstanding Shares1,920,000Free Float1,326,000Market Cap$9.29 million OptionableNot Optionable Beta0.90 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:BOLT) was last updated on 9/5/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bolt Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bolt Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.